Castleman Disease and Rosai-Dorfman Disease

Piris, Miguel Á.; Aguirregoicoa, Elena; Montes‐Moreno, Santiago; Celeiro-Muñoz, Catuxa

doi:10.1053/j.semdp.2017.11.014

Cited by 18 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cases of Rosai-Dorfman disease and lymphoma involving the same anatomic site, the histiocytic infiltrate is most often an incidental finding [4,5,[10][11][12]15]. Although recent discoveries have highlighted the role of MAPK/ERK pathway activating mutations in the pathogenesis of Rosai-Dorfman disease [19,21,22,[25][26][27], the underlying biology of Rosai-Dorfman disease coexisting with lymphoma has not yet been elucidated.…”

Section: Discussionmentioning

confidence: 99%

“…The MAPK/ERK cascade is an important regulatory mechanism of cell function that is dysregulated in different solid tumors and hematologic diseases, the latter including many types of histiocytic proliferation including Rosai-Dorfman disease [19,21,22,[25][26][27][28][29][30][31]. Under physiologic conditions, MAPK/ERK signaling is activated by a wide variety of extracellular and intracellular stimuli, including hormones, growth factors and to a lesser extent inflammatory cytokines and environmental stresses [29,30,32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Focal Rosai–Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation

et al. 2019

View full text Add to dashboard Cite

Rosai-Dorfman disease is a rare histiocytic disorder shown to have gene mutations that activate the MAPK/ERK pathway in at least one-third of cases. Most patients with Rosai-Dorfman disease present with bulky lymphadenopathy or extranodal disease, but rarely Rosai-Dorfman disease is detected concomitantly with lymphoma in the same biopsy specimen. The underlying molecular mechanisms of focal Rosai-Dorfman disease occurring in the setting of lymphoma have not been investigated. We report 12 cases of Rosai-Dorfman disease and lymphoma involving the same anatomic site. There were five men and seven women (age, 23 to 77 years) who underwent lymph node (n = 11) or skin (n = 1) biopsy; the lymphomas included nodular lymphocyte predominant Hodgkin lymphoma (n = 6), classical Hodgkin lymphoma (n = 4), small lymphocytic lymphoma (n = 1) and extranodal marginal zone lymphoma (n = 1). The foci of Rosai-Dorfman disease in all cases had S100 protein-positive histiocytes undergoing emperipolesis. No patients had Rosai-Dorfman disease at other anatomic sites at initial diagnosis and at last follow-up (median, 40 months). We performed immunohistochemical analysis to assess activity of the MAPK/ERK pathway in the Rosai-Dorfman disease foci. We also micro-dissected disease foci and analyzed 146 genes using next-generation sequencing in four cases with adequate DNA; the panel included genes previously reported to be mutated in Rosai-Dorfman disease. All cases were negative for gene mutations. Nevertheless, all cases were positive for cyclin D1 and most cases showed pERK expression indicating that the MAPK/ERK pathway is active in the histiocytes of focal Rosai-Dorfman disease. We conclude that focal Rosai-Dorfman disease coexisting with lymphoma is a clinically benign and localized histiocytic proliferation. These data also indicate that the MAPK/ERK pathway is active in focal Rosai-Dorfman disease although we did not identify activating mutations. These findings suggest that the pathogenesis of focal Rosai-Dorfman disease is different from that of usual cases of Rosai-Dorfman disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Focal Rosai–Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Thymic nurse cells play an important part in thymocyte development by forming heterotypic cell-in-cell interactions, that is, emperipolesis (Guyden et al, 2015). Rosai–Dorfmann disease is a histiocytic proliferative disorder, in which emperipolesis can be observed in lymph nodes with mixed inflammatory infiltrate and in the cerebrospinal fluid (Kraeft et al, 2008; Cohen Aubart et al, 2018; Piris et al, 2018). Emperipolesis has also been observed in renal cell carcinoma (Rotterova et al, 2018), squamous cell carcinoma (Tetikkurt et al, 2018), and other cancers, as well as in infectious liver diseases (Hu et al, 2015).…”

Section: Emperipolesismentioning

confidence: 99%

Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review

Wang

et al. 2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The term cell-in-cell, morphologically, refers to the presence of one cell within another. This phenomenon can occur in tumors but also among non-tumor cells. The cell-in-cell phenomenon was first observed 100 years ago, and it has since been found in a variety of tumor types. Recently, increasing attention has been paid to this phenomenon and the underlying mechanism has gradually been elucidated. There are three main related process: cannibalism, emperipolesis, and entosis. These processes are affected by many factors, including the tumor microenvironment, mitosis, and genetic factors. There is considerable evidence to suggest that the cell-in-cell phenomenon is associated with the prognosis of cancers, and it promotes tumor progression in most situations. Notably, in pancreatic cancer, the cell-in-cell phenomenon is associated with reduced metastasis, which is the opposite of what happens in other tumor types. Thus, it can also inhibit tumor progression. Studies show that cell-in-cell structure formation is affected by the tumor microenvironment, and that it may lead to changes in cellular characteristics. In this review, we summarize the different cell-in-cell processes and discuss their role in tumor progression and how they are regulated by different mechanisms.

show abstract

“…On the contrary, in phagocytosis, lysosomal enzymes destroy the comprised cells. Although emperipolesis is the characteristic of RDD, it may appear in other conditions such as Hodgkin lymphoma, multiple myeloma, malign melanoma, neuroblastoma and rhabdomyosarcoma 8 .…”

Section: Clinical Casementioning

confidence: 99%